DVAX Stock Forecast: High-risk Player Amidst Potential COVID Vaccine
The Tesla stock forecast was written by Hugh Camiener, Analyst at I Know First. Bachelor of Arts candidate at Columbia University.
Summary
- Dynavax is a commercial state biopharmaceutical company which develops and commercializes vaccines..
- Dynavax has an FDA approval on their Hepatitis B vaccine, and they have partnered with Sinovac in developing a vaccine for COVID.
- The pandemic has caused a significant decline in Dynavax’s revenue, with their net product revenue falling 71% in comparison to Q2 last year.
- Dynavax’s vaccine partnership with Sinovac has shown positive signs in phase 1 and phase 2 of testing, and their vaccine will be entering phase 3 in Brazil.
- There is a large amount of volatility in the biopharmaceutical industry; amidst Russia’s self-proclaimed vaccine, Dynavax’s stock fell 9.7%.
- Dynavax stock forecast remains a high-risk, high reward option..
